Skip to main content
Erschienen in: Endocrine 2/2018

24.05.2018 | Original Article

Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients

verfasst von: Zahra Razavi, Saba Maher, Javad Fredmal

Erschienen in: Endocrine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the safety/efficacy of intermittent subcutaneous rapid-acting insulin aspart with the standard low-dose intravenous infusion protocol of regular insulin for treatment of pediatric diabetic-ketoacidosis.

Methods

For a prospective randomized-controlled clinical trial on 50 children/adolescents with mild/moderate diabetic-ketoacidosis, the diagnostic criteria for ketoacidosis included: blood glucose level >250 mg/dl, ketonuria>++, venous pH <7.3 and/or bicarbonate <15 mEq/l. Data collected: age, sex, clinical/laboratory parameters including blood sugar, arterial blood gases, urine ketones, severity of diabetic-ketoacidosis, amount of insulin administered to correct acidosis, time to recover from diabetic-ketoacidosis, number of days of hospitalization, and complications. Patients were randomly assigned to intervention (subcutaneous) and control (intravenous) groups. Controls received 0.05–0.1 unit/kg/hour intravenous regular insulin infusion until resolution of diabetic-ketoacidosis and stayed in the intensive care unit. Interventions received 0.15 unit/kg subcutaneous insulin aspart every two hours and stayed in regular medical ward.

Results

From 50 children (age 2–17 years), 56% (28) were females, and 48% (24) had established-type I diabetes. Intervention and control groups had similar baseline clinical/laboratory findings. Average age (years) was 8.6 ± 0.8 for intervention and 8.86 ± 0.7 for control group (p = 0.4) with 64% having moderate diabetic-ketoacidosis. The mean total-dose of insulin units needed for treatment of diabetic-ketoacidosis in intervention (subcutaneous insulin aspart) was lower than controls (intravenous regular insulin) (p < 0.001). No mortality/serious events happened. Three diabetic-ketoacidosis recurrences among interventions and one among controls occurred.

Conclusions

To manage mild/moderate diabetic-ketoacidosis in children/adolescents, subcutaneous rapid-acting insulin aspart is an alternative to intravenous infusion of regular insulin. Subcutaneous insulin treated moderate DKA with faster recovery/shorter hospital stay.
Literatur
2.
Zurück zum Zitat T. Della Manna, L. Steinmetz, P.R. Campos, S.C. Farhat, C. Schvartsman, H. Kuperman, N. Setian, D. Damiani, Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 28(8), 1856–1861 (2005)CrossRefPubMed T. Della Manna, L. Steinmetz, P.R. Campos, S.C. Farhat, C. Schvartsman, H. Kuperman, N. Setian, D. Damiani, Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 28(8), 1856–1861 (2005)CrossRefPubMed
3.
Zurück zum Zitat M. Mazer, E. Chen, Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis. Ann. Emerg. Med. 53(2), 259–263 (2009)CrossRefPubMed M. Mazer, E. Chen, Is subcutaneous administration of rapid-acting insulin as effective as intravenous insulin for treating diabetic ketoacidosis. Ann. Emerg. Med. 53(2), 259–263 (2009)CrossRefPubMed
6.
Zurück zum Zitat H.O. Ersöz, K. Ukinc, M. Köse, C. Erem, A. Gunduz, A.B. Hacihasanoglu, S.S. Karti, Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int. J. Clin. Pract. 60(4), 429–433 (2006)CrossRefPubMed H.O. Ersöz, K. Ukinc, M. Köse, C. Erem, A. Gunduz, A.B. Hacihasanoglu, S.S. Karti, Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int. J. Clin. Pract. 60(4), 429–433 (2006)CrossRefPubMed
8.
Zurück zum Zitat K. Latif, G.E. Umpierrez, J. Stoever., K. Blaho, A. Freire, L. Parks, B. Culbreath, A.E. Kitabchi, Subcutaneous lispro insulin in the treatment of diabetic ketoacidosis. Diabetes 51(Suppl. 2), 427 (2003) K. Latif, G.E. Umpierrez, J. Stoever., K. Blaho, A. Freire, L. Parks, B. Culbreath, A.E. Kitabchi, Subcutaneous lispro insulin in the treatment of diabetic ketoacidosis. Diabetes 51(Suppl. 2), 427 (2003)
9.
Zurück zum Zitat G.E. Umpierrez, K. Latif, J. Stoever, R. Cuervo, L. Parks, A.X. Freire, A.E. Kitabchi, Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am. J. Med. 117(5), 291–296 (2004)CrossRefPubMed G.E. Umpierrez, K. Latif, J. Stoever, R. Cuervo, L. Parks, A.X. Freire, A.E. Kitabchi, Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am. J. Med. 117(5), 291–296 (2004)CrossRefPubMed
10.
Zurück zum Zitat G.E. Umpierrez, R. Cuervo, A. Karabell, K. Latif, A.X. Freire, A.E. Kitabchi, Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 27(8), 1873–1878 (2004)CrossRefPubMed G.E. Umpierrez, R. Cuervo, A. Karabell, K. Latif, A.X. Freire, A.E. Kitabchi, Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 27(8), 1873–1878 (2004)CrossRefPubMed
12.
Zurück zum Zitat Z. Razavi, F. Hamidi, Diabetic ketoacidosis: demographic data, clinical profile and outcome in a tertiary care hospital. Iran. J. Pediatr. 27(3), e7649 (2017)CrossRef Z. Razavi, F. Hamidi, Diabetic ketoacidosis: demographic data, clinical profile and outcome in a tertiary care hospital. Iran. J. Pediatr. 27(3), e7649 (2017)CrossRef
13.
Zurück zum Zitat J.I. Wolfsdorf, J. Allgrove, M.E. Craig, J. Edge, N. Glaser, V. Jain, W.W. Lee, L.N. Mungai, A.L. Rosenbloom, M.A. Sperling, R. Hanas, International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr. Diabetes Suppl 20, 154-179 (2014). https://doi.org/10.1111/pedi.12165 J.I. Wolfsdorf, J. Allgrove, M.E. Craig, J. Edge, N. Glaser, V. Jain, W.W. Lee, L.N. Mungai, A.L. Rosenbloom, M.A. Sperling, R. Hanas, International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr. Diabetes Suppl 20, 154-179 (2014). https://​doi.​org/​10.​1111/​pedi.​12165
15.
Zurück zum Zitat S.W. Lone, E.U. Siddiqui, F. Muhammed, I. Atta, M.N. Ibrahim, J. Raza, Frequency, clinical characteristics and outcome of diabetic ketoacidosis in children with type-1 diabetes at a tertiary care hospital. J. Pak. Med. Assoc. 60(9), 725 (2010)PubMed S.W. Lone, E.U. Siddiqui, F. Muhammed, I. Atta, M.N. Ibrahim, J. Raza, Frequency, clinical characteristics and outcome of diabetic ketoacidosis in children with type-1 diabetes at a tertiary care hospital. J. Pak. Med. Assoc. 60(9), 725 (2010)PubMed
19.
Zurück zum Zitat J.N. Fisher, M.N. Shahshahani, A.E. Kitabchi, Diabetic ketoacidosis: low-dose insulin therapy by various routes. N. Engl. J. Med. 297, 238–241 (1997)CrossRef J.N. Fisher, M.N. Shahshahani, A.E. Kitabchi, Diabetic ketoacidosis: low-dose insulin therapy by various routes. N. Engl. J. Med. 297, 238–241 (1997)CrossRef
24.
Zurück zum Zitat D. Hedeker, R.D. Gibbons. Longitudinal Data Analysis. (Wiley, New Jersey, 2006) D. Hedeker, R.D. Gibbons. Longitudinal Data Analysis. (Wiley, New Jersey, 2006)
25.
Zurück zum Zitat M.H. Kutner, C.J. Nachtsheim, J. Neter. Applied Linear Regression Models. 5th edn. McGraw-Hill/lrwin, Boston, 2005). Chapter 9.1 M.H. Kutner, C.J. Nachtsheim, J. Neter. Applied Linear Regression Models. 5th edn. McGraw-Hill/lrwin, Boston, 2005). Chapter 9.1
Metadaten
Titel
Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients
verfasst von
Zahra Razavi
Saba Maher
Javad Fredmal
Publikationsdatum
24.05.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1635-z

Weitere Artikel der Ausgabe 2/2018

Endocrine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.